Biosion, Inc. Raises ¥200M RMB Financing to Support Further Global Development of Its Innovative Pipeline

Newark, DE, Nanjing CN – Dec 10, 2020. Biosion Inc. (“Biosion”) today announced completion of ¥200 Million RMB (~$30 Million USD) of financing to transition Biosion into a clinical stage company within twelve months. The financing was led by Lapam Capital, joined by Kaiyuan Capital, Oceanpine Healthcare Fund, C&D Emerging Industry Equity Investment, and Zheshang Innovest.

“We are very grateful to the investors for their confidence and support in our innovative pipeline portfolio, our proprietary integrated technology platforms, as well as our senior management team. Funds from this round of financing will be used to support global clinical development of our innovative pipelines, and to strengthen our preclinical development capabilities of innovative discovery engine.” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion.

Mr. Zhihua Yu, the Chairman of Lapam Capital, said: “We are very optimistic for Biosion’s unique and differentiated innovation pipeline, their highly competitive technology platforms, and their development team with global pharmaceutical experience. We look forward to helping Biosion develop its innovative medicines to benefit patients world-wide.”

Biosion’s Chief Operating Officer and member of the Board of Directors, former Vice President of Janssen Pharmaceuticals, Dr. Hugh Davis said: “With our portfolio of over a dozen high-quality preclinical assets from our unique discovery platforms, we are confident that we will be able to quickly advance the global IND filing and clinical development, thus transforming Biosion into a clinical stage biotech company.”

About Biosion, Inc.

Biosion is a global R&D biotech company developing innovative therapeutics in the fields of immuno-oncology and immunologic diseases. The company is building its proprietary pipeline through internal R&D programs, co-development programs with partners and in-licensing efforts.

The Company integrates several internally-derived proprietary technologies,including its H3 hybridoma platform, SynAbTM synergistic antibody technology, SynKronTM bispecific platform, and SynTracerTM HT-endocytosis screening platform, to significantly accelerate its discovery efforts for novel molecules. The company has operations in Newark, Delaware and Nanjing, China. For more information and full pipeline details, please visit www.biosion.com

About Lapam Capital

Lapam Capital is a leading healthcare-focused venture capital firm in China and manages over 4 billion RMB funds. Lapam is the only biomedical professional investment institution that has received funding from the National Social Security Fund so far. Lapam Capital has invested in more than 50 innovative drugs and innovative medical device companies, including Betta Pharmaceuticals, RemeGen, Clover biopharmaceuticals, Binhui Biotech, Eyebright Medical Group, and many other industry elite companies. The number of domestic NDAs and new drugs approved in Lapam investment portfolio is among the best in the industry. Highly recognized in the industry, Lapam Capital is committed to providing their invested bio-pharmaceutical companies with comprehensive value-added services that may play a key role in the development of the company.

About Zhongguancun Kaiyuan Capital

Zhongguancun Kaiyuan Capital is an industry-finance linkage investment fund initiated by Zhongguancun Venture Capital, focusing on early-stage venture capital in the fields of information technology and biomedicine. Zhongguancun Venture Capital is a venture capital business platform under the Zhongguancun Management Committee and Zhongguancun Development Group. It mainly conducts venture capital through fund of funds investment and direct investment, and strives to promote the effective connection of technology and capital.

About Oceanpine Healthcare Fund

Oceanpine Healthcare Fund (“OHF”), a member of the Oceanpine Capital group, is a healthcare venture fund that aims to connect innovation in the US to the Chinese consumer base, and primarily invests in Chinese and US firms with core technologies and proprietary R&D capabilities. We bridge a supply and demand gap exacerbated by limited R&D in China. Our unique “Dual Market” strategy will help our portfolio companies with local resources and guidance, as well as providing diversification and value-realization for investors. We have established extensive partnership with academic institutions in the USA, such as University of Chicago, MD Anderson Cancer Center, etc., to bring the research projects from these institutions to China and achieve successful transformation of technology. Since our establishment, we have invested in multiple outstanding companies in both China and USA, including Human Longevity Inc. (Genome Technology), Edigene (Gene editing), Hua Dao Biotech (CAR-T), etc.

About C&D Emerging Industry Equity Investment

Established in 2014, C&D Emerging Industry Equity Investment is a corporate venture capital backed by Xiamen C&D Co. Ltd(234# of Fortune 500, 2020)and has become one of the most active players in direct equity investment and FoF market with over RMB 8 billion in capital under management. Our vision is to create value and support companies with high growth potential to achieve better development. We focus on investment in innovative and emerging industries such as healthcare, advanced manufacturing, and TMT/consumption.

About Zheshang Innovest

Zheshang Innovest manages the Zhejiang Zheshang Transform and Upgrade Fund of Funds Partnership(Limited Partnership). It is the vice chairman member of Zhejiang Equity Investment Industry Association and the vice chairman member of Zhejiang M&A Federation. The fund of funds was established under the guidance of the Zhejiang Provincial Finance Office with an approved scale of 10 billion RMB.

Media and Investor Contact:

Ailie Su

Biosion USA, Inc.

E-mail: IR@biosion.com

Biosion and ZhenGe Biotech Sign Global Strategic Partnership Agreement Accelerating Biosion’s Innovative Antibody Pipeline for IND Filing

NEWARK, Delaware, USA and NANJING, China, April 9,2020– Biosion Inc. and Shanghai ZhenGe Biotechnology Co. Ltd. jointly announced today that the two parties have signed a global strategic partnership agreement, to launch multiple projects with Biosion’s innovative antibody pipeline and ZhenGe’s CDMO (Contract Development and Manufacturing Organization) antibody technology platforms.

“We are very pleased to establish a strategic partnership with ZhenGeBiotech.” Said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion Inc., “ZhenGe’s advanced one-stop CDMO services will facilitate CMC development of our innovative biologic pipeline and accelerate our timeline for IND filings and clinical development.”

“We look forward to working with like-minded partners,” said Mr. Jianxin Chen, Founder, Chairman and CEO of ZhenGe Biotech. “Biosion’s innovative pipeline and ZhenGe’s industry leading CMC platform complement each other perfectly. I believe our cooperation will greatly promote the development of the next generation therapeutical biologics for patients in need.”

According to this agreement, the two parties will leverage the competitive advantages of Biosion’s innovative antibody discovery pipeline and ZhenGe’s advanced CDMO technology platforms. This partnership is expected to accelerate Biosion’s innovative antibody therapeutic pipelines and at the same time take advantage of ZhenGe’s development capability and manufacturing capacity. ZhenGe will provide Biosion with strong support in process development and production efficiency to accelerate Biosion’s new biologic clinical trial applications (IND) in China and globally. Details of the partnership terms were not disclosed.

About Biosion, Inc.

Biosion, Inc. is a global biotechnology company, focusing on the discovery and development of innovative therapeutics for oncology and immunological diseases. Leveraging its proprietary H³ (High-throughput, High-content, High-efficiency) antibody platform and SynAb™ technology, the company is committed to discovering and developing innovative biologics for patients with unmet medical needs. Biosion has established a proprietary therapeutic pipeline through its internal discovery efforts and collaborations with other biotech and pharmaceutical companies. For more information, please visit www.biosion.com

About ZhenGe Biotech

Shanghai ZhenGe Biotechnology Co., Ltd., is a nationwide recognized high-tech enterprise registered in the Shanghai Free Trade Zone. ZhenGe specializes in biologics CDMO services. It has an advanced Trinity platform which integrates cell line development, process development and cell culture medium development in synergy. ZhenGe’s capabilities include customized cell culture medium development and production, cell line construction and genetic engineering, and a one-stop service system for biopharmaceutical CMC (Chemistry, Manufacturing, and Control). ZhenGe has recently closed its Series A financing, raising over $51M. Please visit www.zgbiotech.com for more information. 

Biosion, Inc. Appoints Hugh Davis, Ph.D., Chief Operating Officer and President of Biosion USA, Inc.

NEWARKDelaware, and NANJING, China. March 23, 2020 – Biosion Inc., announced the appointment of Hugh M. Davis, Ph.D., as Chief Operating Officer, Biosion, Inc. and President of Biosion USA, Inc.  Dr. Davis joins Biosion from Frontage Laboratories, Inc., where he served as Chief Business Officer.

“We are pleased to welcome Hugh to the executive team and Board of Directors of Biosion. Hugh brings a tremendous wealth of industry experience in biologics research & development and across the biopharmaceutical value chain, including both strategy and execution,” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion, Inc. “Based on our proprietary H³ antibody discovery platform and SynAb™ technology, Biosion has built an innovative biotherapeutics portfolio to address key unmet medical needs of patients with immune and oncology-related diseases. Hugh will be integral to developing and driving portfolio and corporate strategy for the next stage of our growth. He will also oversee our global business operations and clinical development of our innovative therapeutics portfolio.”

Dr. Davis is a seasoned executive with over 30 years of experience in the development of biologics therapeutics. At Janssen R &D/Johnson & Johnson, Hugh was Vice President & Head, Biologics Development Sciences, Biophysics and Laboratory Operations. He and his team were instrumental in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvant®, Tremfya® and Darzalex®.  Following his tenure at Janssen R&D, Hugh joined Frontage Laboratories, Inc. as Chief Business Officer, where he played a critical role in leading the company to a very successful IPO in May of 2019. Dr. Davis holds a Ph.D. in Biochemistry from Villanova University, Villanova, PA, USA.

About Biosion, Inc.

Biosion, Inc. is a global biotechnology company, discovering and developing innovative therapeutics for oncology and immunological diseases. Leveraging our proprietary H³ (High-throughput, High-content, High-efficiency) antibody platform and SynAb™ technology, the company is committed to discovering and developing innovative biologics for patients with unmet medical needs. The company is building a proprietary therapeutic pipeline through its innovative internal discovery efforts and through co-development programs in collaboration with biotech and pharmaceutical companies. For more information, visit www.biosion.com

Contacts:
Shengmei Ma
Biosion USA, Inc.
Newark, DE
+1-508-410-6008
shengmei.ma@biosion.com

Ailie Su
Biosion, Inc.
Nanjing, China
+86-199-5241-5530
ailie.su@biosion.com

Biosynergics, Inc. Completes Series A Financing and Company Restructuring

On October 29, 2017, Biosynergics, Inc. (“Biosynergics”), a China-based startup biotech company, announced that it has completed a 30 million RMB Series A financing. The Series A round was exclusively invested in by Shenzhen Renhe Capital. After completion of the financing, Shenzhen Renhe Capital (“SRC”) and Biosynergics co-registered a new entity named as Biosion, Inc. (“Biosion”) in Nanjing, China. Going forward, Biosynergics will operate as a wholly-owned subsidiary of Biosion.

The rationale for restructuring of Biosynergics was driven by three considerations. First, Biosyngerics has developed and directed its core antibody drug discovery business to minimize preclinical drug development risks while accelerating the clinical and commercial antibody drug pipeline success of its current and future biopharmaceutical clients. Second, Biosynergics has successfully recruited highly trained scientific talent to continue its execution on its business plan and will continue putting the effort of attracting more top talents in the near future. Third, the critical investment and restructuring required to create Biosion, now enables a strategic path forward to enhance and expand its capabilities as necessary through a future IPO. The newly established company, Biosion will focus on innovative antibody drug discovery and early preclinical drug development while Biosynergics will continue its existing business scope of In VitroDiagnosis(IVD) critical raw materials supply and CRO services.

Dr. Mingjiu Chen, Founder and CEO of Biosion stated “We are very pleased that our recent achievements and future growth potential were recognized by the Renhe Capital team. Exploiting our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ (Synergistic Antibody) technology, we are able to interrogate very large, program-specific, antibody collections that result in the discovery and development of both First-in-Class and Best-in-Class antibody drug candidates. With SRC’s investment and their capital management experience, we anticipate that our antibody drug discovery pipeline will be accelerated and our corporate operation efficiency will be further optimized.”

“The demonstrated excellent performance of the Biosynergics team to date and the great growth potential of China’s biotechnology industry are the main considerations for today’s investment,” commented Mr. Weichun Ji, CEO of Shenzhen Renhe Capital. “Furthermore, leveraging their core business of innovative antibody drug discovery and early development, Biosion offers a very unique value proposition to its biopharmaceutical partners to increase the speed and success rate of their antibody drug development. Biosion team has demonstrated a combination of great technical expertise, a thoughtful and clear understanding of marketing strategy, and a strong implementation capability. During our due diligence, we have received very positive feedbacks from both Biosion’s current clients and from the experts from the industry. We are truly pleased to work with Biosion team to promote the innovation of China’s antibody drug industry.”

About Biosion, Inc.

Biosion is a China-based biotech company dedicated to the discovery and development of innovative antibody drugs. Based on our proprietary H³ antibody platform and SynAb™ technology, Biosion is committed to develop biological molecules with superior drug properties and/or novel mechanism of actions to known and novel drug targets. In the past years, Biosion team has successfully delivered multiple therapeutic antibody discovery projects to their clients, and established extensive business relations with the well-known biopharmaceutical companies in China. For more information, please visit www.biosion.com.

About Renhe Capital

Founded in 2012, Shenzhen Renhe Captial (SRC) is a professional asset management company. The company’s core management team investment experience has more than 19 years in the capital market with a wide range of network resources and customer resources, along with many fund management companies, securities companies, listed companies to maintain close relations of cooperation. On March 25, 2014, SRC was awarded the joint venture “private equity fund manager registration certificate” for the top 100 filing of the private management agencies by China Securities Investment Fund Association.

Close Bitnami banner
Bitnami